AVTX AVALO THERAPEUTICS INC revenue, earnings and financials
For the quarter ended June 30, 2026, AVALO THERAPEUTICS INC reported revenue of n/a, net income of −$36.4M and diluted EPS of −$0.83; for the fiscal year ended December 2025 revenue was $59.0K, down 86.6% on the year before.
AVTX annual revenue and earnings
- Fiscal year ended Dec 2025: revenue $59.0K, gross profit n/a, operating income −$72.9M, net income −$78.3M (margin -132642.4%), EPS −$5.84
- Fiscal year ended Dec 2024: revenue $441K, gross profit n/a, operating income −$68.5M, net income −$35.1M (margin -7965.8%), EPS −$20.91
- Fiscal year ended Dec 2023: revenue $1.92M, gross profit n/a, operating income −$27.4M, net income −$31.5M (margin -1639.5%), EPS −$113.58
- Fiscal year ended Dec 2022: revenue $18.1M, gross profit n/a, operating income −$37.4M, net income −$41.7M (margin -230.8%), EPS −$1063.00
- Fiscal year ended Dec 2021: revenue $5.40M, gross profit n/a, operating income −$82.1M, net income −$84.4M (margin -1563.1%), EPS n/a
AVTX quarterly revenue and earnings
- Quarter ended Jun 30, 2026: revenue n/a, net income −$36.4M, EPS −$0.83
- Quarter ended Mar 31, 2026: revenue n/a, net income −$19.6M, EPS −$0.98
- Quarter ended Dec 31, 2025 (from the annual report): revenue n/a, net income −$13.7M, EPS −$0.48
- Quarter ended Sep 30, 2025: revenue $0 (down 100.0% year over year), net income −$30.6M, EPS −$2.19
- Quarter ended Jun 30, 2025: revenue n/a, net income −$20.8M, EPS −$1.92
- Quarter ended Mar 31, 2025: revenue n/a, net income −$13.1M, EPS −$1.25
- Quarter ended Dec 31, 2024 (from the annual report): revenue $192K (down 66.3% year over year), net income −$35.3M, EPS $137.13
- Quarter ended Sep 30, 2024: revenue $249K (up 5.5% year over year), net income $23.0M, EPS −$2.83
- Quarter ended Jun 30, 2024: revenue $0 (down 100.0% year over year), net income $98.5M, EPS −$14.07
- Quarter ended Mar 31, 2024: revenue $0 (down 100.0% year over year), net income −$121M, EPS −$141.14
- Quarter ended Dec 31, 2023 (from the annual report): revenue $570K (down 36.4% year over year), net income −$8.17M, EPS $257.98
- Quarter ended Sep 30, 2023: revenue $236K (down 98.4% year over year), net income −$5.23M, EPS −$26.83
- Quarter ended Jun 30, 2023: revenue $643K (down 37.8% year over year), net income −$8.19M, EPS −$140.73
- Quarter ended Mar 31, 2023: revenue $475K (down 59.5% year over year), net income −$9.96M, EPS −$204.00
- Quarter ended Dec 31, 2022 (from the annual report): revenue $896K (up 307.3% year over year), net income −$9.81M, EPS −$1059.61
- Quarter ended Sep 30, 2022: revenue $14.9M (up 1007.3% year over year), net income $3.19M, EPS $0.34
- Quarter ended Jun 30, 2022: revenue $1.03M (down 69.2% year over year), net income −$13.0M, EPS −$1.38
- Quarter ended Mar 31, 2022: revenue $1.17M (up 148.0% year over year), net income −$22.1M, EPS −$2.35
- Quarter ended Dec 31, 2021 (from the annual report): revenue $220K, net income −$19.2M, EPS n/a
- Quarter ended Sep 30, 2021: revenue $1.35M, net income −$17.4M, EPS n/a
AVTX cash flow, buybacks and dividends
- Fiscal year ended Dec 2025: operating cash flow −$51.5M, share buybacks n/a
- Fiscal year ended Dec 2024: operating cash flow −$49.1M, share buybacks n/a
- Fiscal year ended Dec 2023: operating cash flow −$30.7M, share buybacks n/a
- Fiscal year ended Dec 2022: operating cash flow −$26.8M, share buybacks n/a
- Fiscal year ended Dec 2021: operating cash flow −$70.9M, share buybacks n/a
AVTX balance sheet
- Jun 30, 2026: cash $85.4M, total assets $491M, total liabilities $42.1M, shareholders' equity $449M
- Mar 31, 2026: cash $25.0M, total assets $99.9M, total liabilities $31.6M, shareholders' equity $68.3M
- Dec 31, 2025: cash $15.9M, total assets $116M, total liabilities $33.4M, shareholders' equity $83.0M
- Sep 30, 2025: cash $27.0M, total assets $125M, total liabilities $33.6M, shareholders' equity $91.5M
- Jun 30, 2025: cash $42.3M, total assets $127M, total liabilities $22.0M, shareholders' equity $105M
- Mar 31, 2025: cash $125M, total assets $139M, total liabilities $15.9M, shareholders' equity $123M
- Dec 31, 2024: cash $135M, total assets $151M, total liabilities $17.7M, shareholders' equity $133M
- Sep 30, 2024: cash $81.9M, total assets $98.5M, total liabilities $75.7M, shareholders' equity $21.1M
What is AVTX's revenue?
AVALO THERAPEUTICS INC reported $59.0K of revenue for the fiscal year ended December 2025.
Is AVTX profitable?
No. AVALO THERAPEUTICS INC lost $100M over the last four quarters.
What is AVTX's EPS?
Diluted earnings per share over the last four quarters were −$4.48; −$0.83 in the latest quarter.